Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis

Modern Rheumatology

Volumn 22, Issue 3, 2012, Pages 363-369

  Hayashi, Masatoshi ^a   Kojima, Toshihisa ^a   Funahashi, Koji ^a   Kato, Daizo ^a   Matsubara, Hiroyuki ^a   Shioura, Tomone ^b   Kanayama, Yasuhide ^c   Hirano, Yuji ^d   Ishiguro, Naoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shizuoka Kosei Hospital   (Japan)

^c Nagoya Kyoritsu Hospital   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Anti TNF agent; Disease activity; Rheumatoid arthritis; Surgical treatment; Total arthroplasty

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; STROMELYSIN;

ADULT; AGED; ANKLE ARTHROPLASTY; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE ACTIVITY; ELBOW ARTHROPLASTY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROPLASTY, REPLACEMENT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865383089     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0527-3     Document Type: Article

References (21)

1. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9.
2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9. (Pubitemid 29063266)
3. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol. 2010;29:495-500.
4. Kanbe K, Inoue K. Efficacy of arthroscopic synovectomy for the effect attenuation cases of infliximab in rheumatoid arthritis. Clin Rheumatol. 2006;25:877-81. (Pubitemid 44473157)
5. Toki H, Momohara S, Ikari K, Kawamura K, Tsukahara S, Mochizuki T, et al. Return of infliximab efficacy after total knee arthroplasty in a patient with rheumatoid arthritis. Clin Rheumatol. 2008;27:549-50.
6. Dayer JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw. 1994;5:563-71.
7. Dayer JM. The process of identifying and understanding cytokines: From basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18:31-45.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. (Pubitemid 18091653)
9. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451-8.
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Birgham CO III, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2010;62: 2569-81.
11. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
12. Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum. 2006;54:702-10.
13. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 2006;54:3119-25. (Pubitemid 44622081)
14. Seki E, Matsushita I, Sugiyama E, Taka H, Shinoda K, Hounoki H, et al. Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol. 2009;28:453-60.
15. Yano K, Ikari K, Inoue E, Tokita A, Sakuma Y, Hiroshima R, et al. Effect of total knee arthroplasty on disease activity in patients with established rheumatoid arthritis: 3-year follow-up results of combined medical therapy and surgical intervention. Mod Rheumatol. 2010;20:452-7.
16. Trieb K, Schmid M, Stulnig T, Huber W, Wanivenhaus A. Longterm outcome of total knee replacement in patients with rheumatoid arthritis. Joint Bone Spine. 2008;75:163-6.
17. Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis. 2005;64:650-1. (Pubitemid 40469105)
18. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int. 2004;25:331-5. (Pubitemid 39096154)
19. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002;29:667-77. (Pubitemid 34303858)
20. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55:333-7.
21. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25:430-6. (Pubitemid 47091020)